LTB₄

LTB₄ Related Products (30):

By Type:	Pan (4) Selective (16)
By Effects:	Inhibitors (12) Agonists (2) Antagonists (15)

Cat. No.	Product Name	Effect	Purity

HY-19193

CP-105696	Antagonist	99.81%
CP-105696 is a potent and selective Leukotriene B₄ Receptor antagonist, with an IC₅₀ of 8.42 nM.

HY-114641A

BIIL-260 hydrochloride	Antagonist	99.90%
BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor LTB₄ antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB₄ receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB₄ receptor on isolated human neutrophil cell membranes with K_i values of 1.7 nM.

HY-15744

LY255283	Antagonist	98.52%
LY255283 is a LTB₄ receptor (BLT2) antagonist, with an IC₅₀ of ~100 nM for [³H]LTB₄ binding to guinea pig lung membranes.

HY-113330

12S-HHT	Agonist	≥99.0%
12S-HHT (12(S)-HHTrE) is an enzymatic product of prostaglandin H₂ (PGH₂) derived from cyclooxygenase (COX)-mediated arachidonic acid metabolism. 12S-HHT is an endogenous ligand for BLT2 that fully activates BLT2 in vivo. 12S-HHT suppresses UV-induced IL-6 synthesis in keratinocytes, exerting an anti-inflammatory activity.

HY-15874

Fiboflapon	Inhibitor	99.50%
Fiboflapon (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC₅₀ of 76 nM for inhibition of LTB4 in human blood.

HY-W341962

Halometasone	Inhibitor
Halometasone is a corticosteroid compound that can reduce the expression of serum leukotriene B4 (LTB4) and thymic stromal lymphopoietin (TSLP). Halometasone can be used in research on psoriasis and eczematous skin diseases.

HY-115390

14,15-Dehydro Leukotriene B4	Antagonist
14,15-Dehydro Leukotriene B4 (Compound 4) is a LTB4 receptor antagonist. 14,15-Dehydro Leukotriene B4 also has a higher binding affinity for BLT1 with a K_i value of 27 nM and BLT2 with a K_i value of 473 nM. 14,15-Dehydro Leukotriene B4 inhibits LTB4-induced release of lysozymes from rat polymorphonuclear leukoctyes with an IC₅₀ value of 1 µM.

HY-111806

3,7,4'-Trihydroxyflavone	Inhibitor	99.44%
3,7,4'-Trihydroxyflavone (5-Deoxykampferol) is a flavonoid compound that can be isolated from the stems of Rhus javanica var. roxburghiana. 3,7,4'-Trihydroxyflavone has the effect of cleaving DNA in the presence of copper ions. 3,7,4'-Trihydroxyflavone also has anti-inflammatory and antioxidant activities and can scavenge various reactive oxygen species (ROS) and reactive nitrogen species (RNS).

HY-13628

Etalocib	Antagonist	98.74%
Etalocib (LY293111), an orally active leukotriene B₄ receptor antagonist, inhibits the binding of [³H]LTB₄, with a K_i of 25 nM. Etalocib (LY293111) prevents LTB₄-induced calcium mobilization with an lC₅₀ of 20 nM. Etalocib (LY293111) induces apoptosis.

HY-112737

LY223982	Inhibitor	99.65%
LY223982 is a potent and specific inhibitor of leukotriene B4 receptor, with an IC₅₀ of 13.2 nM against [³H]LTB4 binding to LTB4 receptor.

HY-14165

Veliflapon	Inhibitor	99.48%
Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.

HY-15874A

Fiboflapon sodium	Inhibitor	99.46%
Fiboflapon sodium (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC₅₀ of 76 nM for inhibition of LTB4 in human blood.

HY-101438A

Darbufelone mesylate	Inhibitor	99.65%
Darbufelone mesylate (CI-1004 mesylate) is a dual inhibitor of cellular PGF_2α and LTB₄ production. Darbufelone potently inhibits PGHS-2 (IC₅₀ = 0.19 μM) but is much less potent with PGHS-1 (IC₅₀= 20 μM).

HY-113483

20-Carboxy-Leukotriene B4	Inhibitor	≥98.0%
20-Carboxy-Leukotriene B4 (20-COOH LTB4) is a metabolite of Leukotriene B4 (LTB4; HY-107608). 20-Carboxy-Leukotriene B4 binds to the BLT1 receptor with high affinity. 20-Carboxy-Leukotriene B4 inhibits LTB4-mediated neutrophil responses (migration, degranulation, leukotriene biosynthesis).

HY-19304

Amelubant	Antagonist	99.11%
Amelubant (BIIL 284) is a potent, oral and long acting LTB₄ receptor antagonist, negligibly binds to LTB₄ receptor, with K_is of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a proagent of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity.

HY-112741

SB-209247	Antagonist	99.33%
SB-209247 is a selective, high affinity and orally active leukotriene B4 (LTB4) receptor antagonist with a K_i of 0.78 nM. SB-209247 blocks LTB4-induced Ca²⁺ mobilization with an IC₅₀ of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity.

HY-13628A

Etalocib sodium	Antagonist
Etalocib (LY293111) sodium, an orally active leukotriene B₄ receptor antagonist, inhibits the binding of [³H]LTB₄, with a K_i of 25 nM. Etalocib sodium prevents LTB₄-induced calcium mobilization with an lC₅₀ of 20 nM. Etalocib sodium induces apoptosis.

HY-114873

LY256548	Inhibitor
LY256548 (LY25648) is an orally available anti-ischemic and anti-inflammatory compound with central nervous system activity. LY256548 is an inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and COX, and inhibits A23187 (HY-N6687)-stimulated leukotriene B4 production. LY256548 inhibits bone damage and paw swelling in the rat Freund's complete adjuvant-induced arthritis (FCA) model.

HY-142521

BLT2 probe 1
BLT2 probe 1 (compound 13) is a fluorescent probe based on the synthetic BLT2 agonist CAY10583. BLT2 is a promising target for diabetic wound healing and gastrointestinal lesions. BLT2 probe 1 is suitable to investigate the pharmacology of BLT2 receptor ligands in a variety of assay systems.

HY-149082

LTB4 antagonist 1	Antagonist
LTB4 antagonist 1, a carboxamide-acid compound, is a potent Leukotriene B4 (LTB4) antagonist with an IC₅₀ of 288 nM. LTB4 antagonist 1 has significant anti-inflammatory properties.

Name
Email *

	Sorry, but the email address you supplied was invalid.